InvestSMART

HeraMED Limited (ASX:HMD)

ALERT: Price-sensitive ASX Announcement for HMD
Current share price for HMD : $0.042 -0.001 (-2.33%)+
Announcement
Release
30 Jan 2026 9:48AM
Price at Release
$0.043
Full Release
download
Summary
HeraMED Limited, an innovative medical data and technology company, reported its quarterly activities and cash flow for the December 2025 quarter. The company has achieved significant milestones, including commercial agreements with Philips and Lee Health, strengthening its presence in the US market. HeraMED's proprietary platform, HeraCARE, has been central to its strategy of improving maternity care, recording over 167,000 maternal measurements. The company plans to leverage its data assets for early clinical interventions and has also achieved Class IIb approval for its HeraBEAT device in Australia. Financially, the company reported a cash balance of $1.37 million at the end of the quarter, with a modest operating cash outflow of $690k being the lowest since June 2020, indicating effective cost management and restructuring efforts. A capital raise of $3.2 million was announced to support future operations.
Key Points
  • HeraMED completed agreements with Philips and Lee Health to expand in the US.
  • 167,000 maternal measurements recorded on the HeraCARE platform.
  • Class IIb approval for HeraBEAT in Australia achieved.
  • Operating cash outflow was $690k, the lowest since June 2020.
  • A $3.2 million capital raise was announced for future operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.